Analyst Update: ISIS Pharmaceuticals, Inc., Seadrill Ltd, and Visa Inc

Analysts adjusted their ratings on ISIS, SDRL, and V

by Alex Eppstein

Published on Dec 8, 2014 at 2:04 PM
Updated on Apr 20, 2015 at 5:32 PM

Analysts are weighing in today on drugmaker ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), oil rig operator Seadrill Ltd (NYSE:SDRL), and credit card giant Visa Inc (NYSE:V). Here's a quick look at today's brokerage notes on ISIS, SDRL, and V.

  • ISIS has jumped 9% this afternoon to trade at $57.51, after a number of brokerage firms responded positively to the company's recent drug trial data. Specifically, Piper Jaffray upped its price target to $81, BMO lifted its target to $75, and Stifel Nicolaus boosted its target to $66 -- with the latter two reiterating the equivalent of a "buy" recommendation. Longer term, shares of ISIS Pharmaceuticals, Inc. have gained more than 43% year-to-date. As such, traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been buying to open calls over puts at an annual-high rate in recent weeks. ISIS' 10-day call/put volume ratio of 32.98 outstrips all other readings from the past 12 months.

  • SDRL is down nearly 5% at $11.72, following a pair of price-target cuts from Cowen and Company (to $12 from $27) and Credit Suisse (to $15 from $20), with both reaffirming the equivalent of a "hold" opinion. In fact, the stock earlier touched another five-year low of $11.55. Not surprisingly, short sellers have been turning up the heat on Seadrill Ltd. Short interest rose 16.4% during the most recent reporting period, and now accounts for 8.4% of SDRL's total available float.

  • V raced to a record high of $265.63 this morning, and was last seen up 0.2% at $263.87. Sparking the rally was a price-target boost to $299 from $251 at Nomura, which also repeated its "buy" rating. Given Visa Inc's technical tenacity, option players have been upping the bullish ante at a breakneck pace over the last two weeks. The stock's 10-day ISE/CBOE/PHLX call/put volume ratio of 3.50 rests at the top of its annual range. The brokerage crowd is similarly bullish, as V has received 20 "buy" or better recommendations, compared to four "holds" and not a single "sell."

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....
Tiffany Stock Drops as Takeover Talks Dissipate
LVMH was to acquire Tiffany & Co in a billion-dollar deal
Coty Stock Glows Up with Possible Kardashian Cosmetics Line
The trendy cosmetics company is in talks with reality TV star Kim Kardashian West over a line of beauty products
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.